Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Craif

Explore full profile

Molecular diagnostics company specializing in miRNA-based early cancer detection platform

Tokyo, JapanFounded 2018Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2025
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Craif and the history behind them.

About Craif

Craif Inc. is a molecular diagnostics company focused on developing innovative solutions for early cancer detection using miRNA-based technology. Founded in May 2018 by Ryuichi Onose and Yasui Takao, the company operates in the life sciences sector, serving healthcare providers, medical researchers, and diagnostic laboratories. Craif's core product is a miRNA-based platform designed to identify cancer at its earliest stages, thereby improving patient outcomes and reducing healthcare costs. The company generates revenue through the sale of diagnostic tests and partnerships with healthcare institutions and research organizations. Craif was selected for the 2024 Medtech Innovator Accelerator Cohort, highlighting its potential and innovation in the medical technology field.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Tokyo, Japan
Employees
53
Open positions
1
Dealroom signal
84.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedIn

Latest news

Press, funding announcements and product moves mentioning Craif.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jun 2025 — — Wing Capital Partners · Nagase ↗
SERIES COther financing Apr 2025 $22M $100M Daiwa House · TAUNS Laboratories · Unreasonable Group · Aozora Bank ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Craif website traffic

Latest recorded traffic for Craif is 10K monthly website visits, up 4.2% over the last three months. Craif's team grew 1.9% over the past year.

Latest monthly visits10K 3-month web change+4.2% 1-year team growth+1.9%
Monthly website visitsMay 2023–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
10/15!|Craif Business MeetupTokyo, Tokyo, Japan · Business Development · Aug 19, 2026 @/1,800Tokyo, Tokyo, Japan · Other · Jul 8, 2026
2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
PrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy Jette, Belgium Operational 9 $130M $352M
Strike PharmaDevelops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology Uppsala kommun, Sweden Operational
PROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables Cologne, Germany Operational
OlgramInnovations from the sea to tackle antibiotic resistance | Olgram Paris, France Operational
Asgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming Lund Municipality, Sweden Operational
CARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor Xuhui District, China Operational
Annexon BiosciencesBiotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders San Francisco, United States Operational
ElasmogenNext generation therapeutic biologics company discovering and developing drugs Aberdeen, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Saisei Ventures
  • Global Brain Corporation

Series B and later8 investors entered at this stage

  • Toyoda Gosei
  • X&
  • Daiwa House
  • TAUNS Laboratories
  • Unreasonable Group
  • Aozora Bank
  • Wing Capital Partners
  • Nagase

Other known investors4 additional known investors

  • ANRI
  • Japan Science and Technology Agency
  • Mori Trust
  • Nagoya University

Talent

Book a demo to see the people
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇯🇵 Japan87.5%
🇺🇸 United States12.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Craif on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Craif’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.